Amgen and Takeda Pharmaceutical Co. Ltd. entered an agreement under which Takeda will develop and commercialize as many as 13 molecules from Amgen’s pipeline for the Japanese market. The collaboration includes early to mid-clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.           Under the terms of the agreement, Amgen will receive an upfront cash payment of $200 million. Takeda will also pay to Amgen as much as $340 million in expect...